Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods

Public Health Genomics

Volumn 19, Issue 3, 2016, Pages 187-191

  Leyens, Lada ^a   Brand, Angela ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adaptive pathways; Early dialogue; European Medicines Agency; Food and Drug Administration; Health technology assessment; Innovative medicines; Marketing authorization application

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; MARKETING; MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY; PRIORITY JOURNAL; BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG APPROVAL; EUROPE; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PROCEDURES; UNITED STATES;

DRUG APPROVAL; EUROPE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MARKETING; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84977110614     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000446537     Document Type: Article

References (8)

1. Adams C, Bran V: Spending on new drug development. Health Economics 2010; 19: 130-141.
2. Berntgen M, Gourvil A, Pavlovic M, Goettsch W, Eichler H-G, Kristensen F: Improving the contribution of regulatory assessment reports to health technology assessments - a collaboration between the European Medicines Agency and the European network for Health Technology Assessment. Value Health 2014; 17: 634-641.
3. European Parliament: Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines. Policy Department A: Economic and Scientific Policy. Brussels, European Union, 2015.
4. Hart D: Heilversuch und klinische Prüfung. Kongruenz und Differenz. Medizinrecht 2015; 33: 766-775.
5. Leyens L, Richer É, Melien Ø, Ballensiefen W, Brand A: Available tools to facilitate early patient access to medicines in the EU and the USA: analysis of conditional approvals and the implications for personalized medicine. Public Health Genomics 2015; 18: 249-259.
6. Lockwood P, Ewy W, Hermann D, Holford N: Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res 2006; 23: 2050-2059.
7. Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, et al: Early market access of cancer drugs in the EU. Ann Oncol 2016; 27: 96-105.
8. NICE: Note to describe procedures at NICE to support the early access to medicines scheme. https://www.nice.org.uk/Media/Default/ About/Who-we-are/Policies-and-procedures/ eams-process-jan-16.pdf (accessed April 10, 2016).